Of the participants who resumed cART , 30 ( 34 % ) were in the Vacc-4x group and 11 ( 29 % ) in the placebo group , and percentage changes in CD4 counts were not significant ( mean treatment difference -571 , 95 % CI -1301 to 159 ) .